Germany-headquartered cellular technology developer Singleron Biotechnologies has closed a series B round sized at almost $100m that included investment vehicles for pharmaceutical firm Eli Lilly and internet and telecommunications group SoftBank.
Lilly Asia Ventures and SBCVC were joined in the round by Lake Bleu Capital, Firstred Capital, MSA Capital, Sherpa Healthcare Partners, Arch Venture Partners, CDG Capital, CDH Investments, Superstring Capital and 3W Partners.
Singleron provides single-cell multiomics products such as laboratory instruments, microfluidic systems, reagents, software and database platforms for use in research and clinical testing.
The series B funding will support product development and international expansion in addition to the pursuit of regulatory approval for the company’s in vitro diagnostics technology.
Oriza Holdings and Frees Fund combined to invest ‘millions of dollars’ in Singleron in 2018 and returned for a $14.1m pre-series A round in mid-2019 that also featured Sherpa Healthcare Partners and China Growth Capital.
The company subsequently secured $30m in a September 2020 series A round led by Lilly Asia Ventures and backed by Tencent, Arch Venture Partners, Sherpa Healthcare Partners, China Growth Capital and Chenling Asset Management.
Singleron added over $10m two months later in a series A-plus round backed by Softbank China Venture Capital, Lilly Asia Ventures, CDG Capital and CDH Investments.
Internet group Tencent then led the company’s $30m series A2 round in December 2020, investing alongside SBCVC, Lilly Asia Ventures, CDH Investments and Sherpa Healthcare Partners.
